Two novel variants in GRN: the relevance of CNV analysis and genetic screening in FTLD patients with a negative family history
Julie F. H. De Houwer,Elise G. P. Dopper,Ana Rajicic,Renee van Buuren,Marina Arcaro,Daniela Galimberti,Guido J. Breedveld,Martina Wilke,Rick van Minkelen,Lize C. Jiskoot,John C. van Swieten,Laura Donker Kaat,Harro Seelaar
DOI: https://doi.org/10.1007/s00415-024-12758-7
2024-12-18
Journal of Neurology
Abstract:Background Frontotemporal lobar degeneration (FTLD) is one of the leading causes of early onset dementia. Pathogenic variants in GRN have been reported to cause 5–25% of familial and 5% of sporadic FTLD. Here, we present two novel, likely pathogenic variants in GRN . Methods Four patients from four different families underwent whole exome sequencing (WES) with additional copy-number variance (CNV) analysis in a clinical setting. TMEM106B rs1990622 and rs3173615 SNPs and 3'UTR insertion were tested in one presymptomatic carrier. In three probands and one presymptomatic carrier, plasma progranulin (PGRN) levels were measured using a specific ELISA kit. In two probands, neuropathological diagnosis was established using current neuropathological criteria. Results Through CNV analysis on WES data, we identified a partial deletion, NM_002087.2 ( GRN ):c.1179 + 104_1536delinsCTGA, p.(?), in three patients with primary progressive aphasia and/or corticobasal syndrome. Haplotype analysis revealed a shared haplotype block, suggesting that the deletion represents a founder mutation. Additionally, we found a novel, missense variant, NM_002087.2 ( GRN ):c.23 T > A, p.(Val8Glu), in one proband with a negative family history. The proband's unaffected parent—in their 80 s—carried the same variant, yet was homozygous for the TMEM106B risk haplotype. The pathogenicity of both GRN variants was supported by typical neuropathological features and reduced PGRN levels. Conclusion We recommend a thorough genetic screening, including CNV analysis, for both familial and apparent sporadic FTLD patients. Furthermore, the presymptomatic carrier homozygous for the TMEM106B risk haplotype exemplifies the presence of other protective factors that modify disease onset and urges caution in genetic counselling based on the TMEM106B haplotype.
clinical neurology